Biblio Discovery — Demo Discovery Service

12 results for "Lisa Bodei"

Showing 1–12 · 0.94 seconds · RSS

  1. Journal Article

    Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm PathobiologySummary

    Mark Kidd; Irvin M. Modlin; Lisa Bodei et al.

    Cellular and Molecular Gastroenterology and Hepatology, Vol. 1 No. 2 · 2015 · English · DOAJ Scopus

    Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN), considered a heterogeneous neoplasia, exhibit ill-defined pathobiology and protean symptomatology and are ubiquitous in location. They are difficult to diagnose, challenging to manage, and outcome depends on cell type, secretory product…

  2. Journal Article Full text

    Utility of a ready-to-use PCR system for neuroendocrine tumor diagnosis

    Mark Kidd; Ignat A. Drozdov; Somer Matar et al.

    PLOS ONE, Vol. 14 No. 6 · 2019 · English · PLOS Scopus

    Background: Multigene-based PCR tests are time-consuming and limiting aspects of the protocol include increased risk of operator-based variation. In addition, such protocols are complex to transfer and reproduce between laboratories. Aims: Evaluate the clinical utility of a pre-spotted PCR plate…

    Also available at: DOAJ

  3. Journal Article

    NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging

    Anna Malczewska; Magdalena Witkowska; Karolina Makulik et al.

    Endocrine Connections, Vol. 8 No. 4 · 2019 · English · DOAJ Scopus

    Introduction: Current monoanalyte biomarkers are ineffective in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). NETest, a novel multianalyte signature, provides molecular information relevant to disease biology. Aim(s): Independently validate NETest to diagnose GEP-NETs and identify…

  4. Journal Article Full text

    EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds

    Manuel Weber; Marnix G. E. H. Lam; Carlo Chiesa et al.

    European Journal of Nuclear Medicine and Molecular Imaging · 2022 · English · OpenAlex Scopus

    Primary liver tumours (i.e. hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC)) are among the most frequent cancers worldwide. However, only 10-20% of patients are amenable to curative treatment, such as resection or transplant. Liver metastases are most frequently caused by…

  5. Journal Article

    Precision imaging and evolving therapies in paragangliomas and pheochromocytomas: from molecular diagnostics to imaging-guided management

    Aurelie Choucair; Anna Zdunek; Matthew Liao et al.

    Insights into Imaging, Vol. 17 No. 1 · 2026 · English · DOAJ Scopus

    Abstract Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors originating from neural crest-derived chromaffin tissue, marked by clinical heterogeneity and substantial genetic underpinnings. With up to 70% of cases linked to germline or somatic mutations, including Succinate…

  6. Journal Article Full text

    Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

    Clemens Kratochwil; Wolfgang P. Fendler; Matthias Eiber et al.

    European Journal of Nuclear Medicine and Molecular Imaging · 2023 · English · OpenAlex Scopus

    Abstract Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically significant prostate adenocarcinomas, and patients with target-positive disease can easily be identified by PSMA PET imaging. Promising results with PSMA-targeted radiopharmaceutical therapy have already…

  7. Journal Article

    A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management

    Kjell Oberg; Eric Krenning; Anders Sundin et al.

    Endocrine Connections, Vol. 5 No. 5 · 2016 · English · DOAJ Scopus

    The complexity of the clinical management of neuroendocrine neoplasia (NEN) is exacerbated by limitations in imaging modalities and a paucity of clinically useful biomarkers. Limitations in currently available imaging modalities reflect difficulties in measuring an intrinsically indolent disease…